PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15086213-1	2004	BACKGROUND/AIMS: Based on former studies in experimental animals on the effect of octreotide on serum and ascitic levels of tumor necrosis factor-alpha and interleukin-6 in the field of necrotizing pancreatitis, the present study was designed to investigate the effect of octreotide on serum interleukin-6 of patients with acute edematous pancreatitis.	Octreotide	82-92	tumor necrosis factor	Homo sapiens	124-151	
23086244-7	2012	Supplement of octreotide also accompanied with reduction in plasma levels of tumor necrosis factor alpha and IL-6.	Octreotide	14-24	tumor necrosis factor	Homo sapiens	77-104	
21692635-2	2011	We have demonstrated that Octreotide inhibits only LPS induced secretion of proinflammatory cytokines including TNFa by Kupffer cells (KC).	Octreotide	26-36	tumor necrosis factor	Homo sapiens	112-116	
21692635-12	2011	TNF? mRNA expression was inhibited by Octreotide and a significant inhibition was observed at 48?h.	Octreotide	38-48	tumor necrosis factor	Homo sapiens	0-4	
19373973-0	2009	Randomized study of the effect of pentoxifylline or octreotide on serum levels of TNF-alpha and IL-6 after endoscopic retrograde cholangiopancreatography.	Octreotide	52-62	tumor necrosis factor	Homo sapiens	82-91	
19373973-1	2009	OBJECTIVES: To study the effect of pentoxifylline and octreotide administration on serum levels of TNF-alpha and IL-6, in patients who underwent endoscopic retrograde cholangiopancreatography (ERCP), whether they developed pancreatitis or not.	Octreotide	54-64	tumor necrosis factor	Homo sapiens	99-108	
19373973-8	2009	TNF-alpha levels at the 24 h were lower than baseline in patients with pancreatitis who received octreotide (P = 0.04).	Octreotide	97-107	tumor necrosis factor	Homo sapiens	0-9	
19373973-10	2009	Pentoxifylline and octreotide cannot prevent IL-6 elevation but octreotide reduces TNF-alpha levels, which may have an impact on the severity of post-ERCP pancreatitis.	Octreotide	64-74	tumor necrosis factor	Homo sapiens	83-92	
9854685-8	1998	In addition we evaluated the effect of acute octreotide administration on serum TNF-alpha and IL-I concentrations.	Octreotide	45-55	tumor necrosis factor	Homo sapiens	80-89	
23275042-9	2013	High-dose octreotide administration within 48h after AP onset may efficiently reduce the risk of SAP developing and partly attenuate SAP through raising plasma SST to a normal level and decreasing IL-6 and TNF-alpha.	Octreotide	10-20	tumor necrosis factor	Homo sapiens	206-215